(+)-PM 92131 is the active enantiomer of (±)-PM 92131. (+)-PM 92131 is a non-nucleoside HIV-1 inhibitor. (+)-PM 92131 has an anti-HIV-1 activity with EC50s of 0.8 and 0.6 μM for HIV-1 RF strain in XTT cytoprotection and syncytium-forming assay, respectively. (+)-PM 92131 can be used for HIV infections research.

Org 274178-0 is a selective thyroid-stimulating hormone receptor (TSHR) antagonist with a pIC50 value for TSHR is 5.03. Org 274178-0 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 is promising for research of Graves’ disease and Graves’ ophthalmopathy.

GSK1842799 is an orally active selective S1P1 receptor agonist prodrug. GSK1842799 is promising for research of multiple sclerosis.

PPI-4955 is a subtype 1 (S1P₁) agonist of sphingosine-1-phosphate receptor with an EC50 of 1.62 nM. PPI-4955-P (the active phosphorylated form) exhibits excellent receptor selectivity and affinity, and the IC50 values for hS1P₁, hS1P₃, hS1P₄, and hS1P₅ are 0.23, 2000, 6.5, and 184 nM respectively. PPI-4955 has significantly improved in vivo phosphorylation efficiency, which can reduce lymphocytes and improve cardiovascular risk. PPI-4955 can be used in immunomodulation research.

Isoapoptolidin is a mitochondrial F0F1-ATPase inhibitor (Ki>100 μM, selective for mitochondrial complex V). Isoapoptolidin is promising for research of mitochondrial energy metabolism-related diseases (e.g., cancer, neurodegeneration).

L-ENIPO (hydrochloride) is an inhibitor of iNOS, nNOS, and eNOS with Ki values of 17, 10.3, and 58.2 μM. L-ENIPO (hydrochloride) exerts reversible tight binding inhibition selective for iNOS with longer incubation time.

Romidepsin (GMP) (FK 228 (GMP)) is Romidepsin produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis.

RAM1147 is a farnesyl pyrophosphate synthase (FPPS) inhibitor. RAM1147 disrupts protein isoprenylation, inhibiting tumor cell proliferation. RAM1147 is promising for research of cancers (e.g., myeloma, breast cancer) and bone metabolism disorders (e.g., osteoporosis).

ML114 is a specific inhibitor of RBBP9 serine hydrolase, with an IC50 of 0.63 μM against recombinant RBBP9. ML114 can inhibit the proliferation of human pluripotent stem cells (hPSCs) by regulating the expression of NFYA and other factors, but does not induce differentiation. ML114 can be used in the research of diseases such as retinoblastoma.

BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant. BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model.

NSC-323241 is a potent STT3A-mediated mega protein complex assembly inhibitor. NSC-323241 disrupts he endoplasmic reticulum (ER) mega complex nucleated by STT3A during dengue virus (DENV) and Zika virus (ZIKV) infection. NSC-323241 targets the binding of STT3A subcomplex with viral nonstructural proteins (e.g., NS2B, NS3) and host translocon proteins, disrupting the formation of viral replication microenvironment. NSC-323241 is promising for research of flavivirus infection, such as dengue fever and Zika virus.

MRSA antibiotic 3 (Compound C8) is a small-molecule antibiotic active against Methicillin)-resistant Staphylococcus aureus (MRSA), showing a MIC of 0.5 μg/mL against the standard S. aureus strain (ATCC 29213). MRSA antibiotic 3 potently inhibits the ATPase activity of S. aureus DNA gyrase with an IC50 of 0.32 μM. MRSA antibiotic 3 exhibits strong inhibitory activity against five clinical MRSA isolates, with MIC values ranging from 0.5 to 1 μg/mL. MRSA antibiotic 3 demonstrates negligible cytotoxicity at effective antibacterial concentrations and causes no hemolysis in erythrocytes even at extremely high concentrations. MRSA antibiotic 3 shows significant protective effects in both Galleria mellonella infection and murine sepsis models.

TCB-32 (Compound I-1) is a FGFR1 agonist with an EC50 of 0.88  μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK 1/2 with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.

(Z)-Heptaprenyl-MPDA ((Z)-Heptaprenyl phosphate) diammonium is the (Z)-isomer of Heptaprenyl-MPDA. Heptaprenyl-MPDA (Heptaprenyl phosphate) is a short-chain homolog of undecaprenyl phosphate, is an endogenous substrate of Phospho-MurNAc-pentapeptide translocase (MraY). Heptaprenyl-MPDA can be used for bacterial infections research.

Phytoene (trans-Phytoene) is a carotene pigment. Phytoene is the precursor of all carotenoids. Phytoene is the predominant PT isomer in most carotenogenic organisms. Phytoene can delay the skin tumors appearance and reduce their number in mice that are induced the tumors with UV-B light. Phytoene leads to protection against oxidative stress and malignant transformation. Phytoene inhibits the proliferation of breast cancer cells.

Δ²-Avermectin B₁ₐ (Compound 3) is an antiparasitic agent targeting glutamate-gated chloride channels (GluCls) in the neuromuscular system of invertebrates. Δ²-Avermectin B₁ₐ enhances chloride ion influx, leading to hyperpolarization of the neuromuscular cell membrane, inhibition of neural signal transmission, and ultimately paralysis and death of parasites. Δ²-Avermectin B₁ₐ is promising for research of agricultural pests.

SARS-CoV-2 Mpro ligand 1 (Compound S15) is a PROTAC target protein ligand. SARS-CoV-2 Mpro ligand 1 can be used to synthesize BP-198.

RS130-180 is a selective β-arrestin-biased agonist targeting the serotonin 2A receptor (5-HT2aR). RS130-180 is promising for research of neuropsychiatric disorders such as depression.

Thalidomide-NH-alkynes is a synthesized E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC HDAC degrader-2.

VU439 is a functionalized photoaffinity ligand of Elexacaftor). VU439 retains the activity of Elexacaftor as a CFTR corrector and can identify SCCPDH as a specific off-target of Elexacaftor through chemoproteomics.

iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma.

iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma.

MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities Kd ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer.

DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research.

DEL1187-126-5-80 is a JAK3 inhibitor with IC50s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases.

(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC50 of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis.

L-767685, the ethyl ester prodrug of L-767679), is a non-peptide glycoprotein IIb/IIIa receptor (GPIIb-IIIa receptor) antagonist. L-767679 has a potent anti-platelet aggregation effect. L-767685 can be used for research on antithrombosis.

TBE56, a molecular glue, is a BACH1 degrader, with an EC50 of 44 nM. TBE56 is a weak NRF2 inducer and the biotinylated TBE31. TBE56 interacts and promotes the degradation of BACH1 via a mechanism involving the E3 ligase FBX022. TBE56 reduces intracellular Fe2+ accumulation, ROS generation, and malondialdehyde (MDA) content, while increasing GSH/GSSG ratio and upregulating GPX4 in Prominin-2-overexpressed BMSCs. TBE56 significantly ameliorates intervertebral disc degeneration (IVDD) in puncture-induced SD rat IVDD model. TBE56 can be used for the study of intervertebral disc degeneration (IVDD).

(S,R,S)-AHPC-Me-amide-C4-Br incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-Me-amide-C4-Br can be used to design PROTAC, such as PROTAC ERK5 degrader-1.

Piperidine-azetidine-Br is a PROTAC linker that can be used in the synthesis of PROTACs, such as BY13.